Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy.
about
Neurotoxins: free radical mechanisms and melatonin protectionAntioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsisOxidative Stress-Mediated Skeletal Muscle Degeneration: Molecules, Mechanisms, and TherapiesBioactive compounds derived from the yeast metabolism of aromatic amino acids during alcoholic fermentationNutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the ConjectureMelatonin as a Potential Agent in the Treatment of SarcopeniaRadiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposureInflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMDDietary Sources and Bioactivities of MelatoninMelatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways.Melatonin Therapy in Patients with Alzheimer's Disease.Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function.Therapeutic application of melatonin in mild cognitive impairment.Melatonin: buffering the immune systemMultiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin.Mitochondrial DNA and inflammatory diseases.Melatonin as a natural ally against oxidative stress: a physicochemical examination.Exercise and melatonin in humans: reciprocal benefits.Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.Melatonin regulates mesenchymal stem cell differentiation: a review.Optimizing Bone Health in Duchenne Muscular Dystrophy.Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing-remitting multiple sclerosis patients.Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules.The benefit of a supplement with the antioxidant melatonin on redox status and muscle damage in resistance-trained athletes.Neuroprotective Mechanisms of Melatonin in Hemorrhagic Stroke.Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophyRetinoblastoma-independent regulation of cell proliferation and senescence by the p53-p21 axis in lamin A /C-depleted cells.Melatonin restores muscle regeneration and enhances muscle function after crush injury in rats.Melatonin alleviates lipopolysaccharide-induced hepatic SREBP-1c activation and lipid accumulation in mice.Melatonin alleviates lipopolysaccharide-induced placental cellular stress response in mice.Fluid shear stress and melatonin in combination activate anabolic proteins in MC3T3-E1 osteoblast cells.Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations.Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas.Expansion of CD11b+Ly6Ghigh and CD11b+CD49d+ myeloid cells with suppressive potential in mice with chronic inflammation and light-at-night-induced circadian disruption.Melatonin prevents hypochlorous acid-mediated cyanocobalamin destruction and cyanogen chloride generation.Melatonin Treatment Reduces Oxidative Damage and Normalizes Plasma Pro-Inflammatory Cytokines in Patients Suffering from Charcot-Marie-Tooth Neuropathy: A Pilot Study in Three Children.Melatonin attenuates hypochlorous acid-mediated heme destruction, free iron release, and protein aggregation in hemoglobin.Melatonin behavior in restoring chemical damaged C2C12 myoblasts.Melatonin prolongs graft survival of pancreas allotransplants in pigs.
P2860
Q22305781-FF21D646-A2FB-4ADB-AD83-B976DCE99C75Q24622152-DEE2DF5A-7E75-419C-8227-38E52AC6B000Q26769962-C63FCE9E-AF79-46FD-B14E-29E1C8AE6A8FQ26823359-DAF13AD8-765E-46E1-AD32-7548EA0A341DQ28072269-DBD33A71-7801-46A0-BD01-7325DD1FC7D4Q28076649-5BDD9A90-51D5-4835-A670-A6D623D41BA9Q28387506-145916BB-AB7D-421B-B567-D0DD561247B3Q28389778-AFDCF903-646F-4B26-9D10-8B52EC0EC023Q33616780-322B5ECB-DEE0-4545-B005-8B264FA55370Q33864136-946F9955-D85A-483E-8EC9-C6C82E55E072Q36335048-E87E93BA-6C13-4D3D-B7EA-46350931A537Q36351040-8408C7CA-75BF-4533-84FC-7420FAADA502Q36576496-CFBF3414-CF3F-4D33-8190-DC929F2602F4Q36820644-CA0C22DC-9CF4-41D6-AAB4-5B92454C9088Q37813804-F5FDA29F-06BA-4239-A79E-811BE28F3708Q37898562-97065A87-D231-430B-BAAC-77F93A012D24Q37900675-BA22F39F-0814-43A0-A698-B58E707D6A50Q37919169-4963C642-5904-4218-BCC0-1B2C44A35817Q38022179-A7CD934A-0ACE-4104-9CFC-DE9D16649040Q38197694-F0F0EC29-4705-48E1-9F3C-14F8893F3F11Q38540530-61930F25-E97D-4A3F-BE23-6D58E5C6C17DQ38632025-69F75FED-36A6-4F31-AE2D-9939D2B5FC08Q38888495-C65D7532-FDD2-4BDD-A8A9-467EBFDEFF4DQ38963952-F943B083-C9E7-47AA-90D6-48EF416206AEQ39108088-476019DA-5069-446A-AF55-16F6E86759EDQ39410461-61C4C005-41DF-4DD9-B877-FDB88839D3D0Q39550057-98CE1AC8-DA7D-4242-BAD1-A9E89AFEA6E4Q42610763-66091F2A-2340-4426-9747-D908BC604AE3Q42732005-DD9A943B-DF53-4A0E-BDD0-1ABBDC4BA42EQ42748318-6481B2F9-699B-447F-B1B3-DA93CC063D21Q42825651-F60A9086-F077-47F0-93DB-72F386752CAFQ44208373-CA3BB64A-10C9-448C-9205-CB5EE109EFB6Q46238476-9DF43653-D8D2-4D37-8493-AC7C18F51D64Q46313066-09E11C38-D630-4FE9-BF3D-B324EE8F7EEDQ47808999-2AEF9F9A-AF74-4A2C-AE35-EDD03BE6F490Q48105975-6B957EDE-B590-4174-812D-E8F64A5135DCQ48180636-AAFE301E-04E1-4682-8042-1C22D2CCD6ACQ50514102-AD3BDB7F-4062-469E-9F49-1640EB6F1365Q50863046-D4A2D641-AADA-4138-BA4D-AF7E8AF4BFCBQ51023886-9D8C7FB1-EBD5-4219-AACD-050DA8FC10E0
P2860
Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Melatonin treatment normalizes ...... m Duchenne muscular dystrophy.
@en
Melatonin treatment normalizes ...... m Duchenne muscular dystrophy.
@nl
type
label
Melatonin treatment normalizes ...... m Duchenne muscular dystrophy.
@en
Melatonin treatment normalizes ...... m Duchenne muscular dystrophy.
@nl
prefLabel
Melatonin treatment normalizes ...... m Duchenne muscular dystrophy.
@en
Melatonin treatment normalizes ...... m Duchenne muscular dystrophy.
@nl
P2093
P2860
P50
P1476
Melatonin treatment normalizes ...... m Duchenne muscular dystrophy.
@en
P2093
Antonio Molina-Carballo
Antonio Muñoz-Hoyos
Belén Sevilla
Carmen Venegas
José Antonio García
Mariam Chahbouni
P2860
P304
P356
10.1111/J.1600-079X.2010.00752.X
P577
2010-03-04T00:00:00Z